BioCentury | Aug 27, 2001
Company News

Hemoxymed, Ophidian deal

...will retain the HemoXymed name and tissue oxygenation business focus. HemoXymed Inc. , Charlottesville, Va. Ophidian Pharmaceuticals Inc....
BioCentury | Feb 5, 2001
Company News

Hemoxymed, Ophidian deal

...for $1.25 million in cash (see BioCentury, Sept. 11, 2000). HemoXymed Inc. , Charlottesville, Va. Ophidian Pharmaceuticals Inc....
BioCentury | Sep 11, 2000
Company News

Ophidian, Promega deal

...debt and acquire OPHD’s patent portfolio and cGMP facilities for pharmaceutical purification, formulation and packaging. Ophidian Pharmaceuticals Inc....
BioCentury | Aug 21, 2000
Company News

Ophidian management update

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Infectious diseases Resigned: Douglas Stafford as president, CEO and a director WIR Staff Infectious...
BioCentury | May 30, 2000
Company News

Ophidian infectious diseases news

...million on revenues of $27,000 in its fiscal year ended Sept. 30, 1999. (Management, B8) Ophidian Pharmaceuticals Inc....
BioCentury | May 30, 2000
Company News

Ophidian management update

...Restructuring, B7) Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Infectious diseases Resigned: Joseph Firca as VP of R&D...
BioCentury | Jan 31, 2000
Tools & Techniques

In the running

...Status GelTex (GELX) GT160-246 Phase I starts Q2 ImmuCell (ICCC) DiffGAM Phase I/II starts Q2 Ophidian...
BioCentury | Jan 31, 2000
Tools & Techniques

Keeping the faith in MMPIs; C'est difficile

...C. difficile as a target, including Peptide Therapeutics Group plc , Synsorb Biotech Inc. , Ophidian Pharmaceuticals Inc....
...as it is in a quiet period linked to its follow-on offering earlier this month. Ophidian...
BioCentury | Jun 21, 1999
Company News

Ophidian scientific advisory board update

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Autoimmune/Inflammation, Infectious diseases Appointed: Terrence Barrett, assistant professor of gastroenterology at Northwestern University Medical School WIR Staff autoimmune Infectious Inflammation...
BioCentury | Jun 14, 1999
Clinical News

OPHD001: Began Phase II testing

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Product: OPHD001 Business: Autoimmune/Inflammation Therapeutic category: Antibody Target: Clostridium difficile Description: Avian antibody against two C. difficile toxins Indication: Treat C. difficile-associated disease Status: OPHD will begin U.S. Phase...
Items per page:
1 - 10 of 13
BioCentury | Aug 27, 2001
Company News

Hemoxymed, Ophidian deal

...will retain the HemoXymed name and tissue oxygenation business focus. HemoXymed Inc. , Charlottesville, Va. Ophidian Pharmaceuticals Inc....
BioCentury | Feb 5, 2001
Company News

Hemoxymed, Ophidian deal

...for $1.25 million in cash (see BioCentury, Sept. 11, 2000). HemoXymed Inc. , Charlottesville, Va. Ophidian Pharmaceuticals Inc....
BioCentury | Sep 11, 2000
Company News

Ophidian, Promega deal

...debt and acquire OPHD’s patent portfolio and cGMP facilities for pharmaceutical purification, formulation and packaging. Ophidian Pharmaceuticals Inc....
BioCentury | Aug 21, 2000
Company News

Ophidian management update

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Infectious diseases Resigned: Douglas Stafford as president, CEO and a director WIR Staff Infectious...
BioCentury | May 30, 2000
Company News

Ophidian infectious diseases news

...million on revenues of $27,000 in its fiscal year ended Sept. 30, 1999. (Management, B8) Ophidian Pharmaceuticals Inc....
BioCentury | May 30, 2000
Company News

Ophidian management update

...Restructuring, B7) Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Infectious diseases Resigned: Joseph Firca as VP of R&D...
BioCentury | Jan 31, 2000
Tools & Techniques

In the running

...Status GelTex (GELX) GT160-246 Phase I starts Q2 ImmuCell (ICCC) DiffGAM Phase I/II starts Q2 Ophidian...
BioCentury | Jan 31, 2000
Tools & Techniques

Keeping the faith in MMPIs; C'est difficile

...C. difficile as a target, including Peptide Therapeutics Group plc , Synsorb Biotech Inc. , Ophidian Pharmaceuticals Inc....
...as it is in a quiet period linked to its follow-on offering earlier this month. Ophidian...
BioCentury | Jun 21, 1999
Company News

Ophidian scientific advisory board update

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Business: Autoimmune/Inflammation, Infectious diseases Appointed: Terrence Barrett, assistant professor of gastroenterology at Northwestern University Medical School WIR Staff autoimmune Infectious Inflammation...
BioCentury | Jun 14, 1999
Clinical News

OPHD001: Began Phase II testing

Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Product: OPHD001 Business: Autoimmune/Inflammation Therapeutic category: Antibody Target: Clostridium difficile Description: Avian antibody against two C. difficile toxins Indication: Treat C. difficile-associated disease Status: OPHD will begin U.S. Phase...
Items per page:
1 - 10 of 13